To assess the effect of intepirdine (RVT-101) versus placebo on quantitative and qualitative gait and balance parameters.~Each subject will be randomized 1:1 to one of the following sequences:~Sequence 1: AB = RVT-101 35 mg during the early treatment period and Placebo during the late treatment period~Sequence 2: BA = Placebo during the early treatment period and RVT-101 35 mg during the late treatment period~Treatment A = RVT-101 35 mg once daily.~Treatment B = Placebo once daily.
This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.